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Summary
Background Delayed treatment for first episodes of psychosis predicts worse outcomes. We hypothesised that delaying 
treatment makes all symptoms more refractory, with harm worsening first quickly, then more slowly. We also 
hypothesised that although delay impairs treatment response, worse symptoms hasten treatment, which at 
presentation mitigates the detrimental effect of treatment delay on symptoms.
Methods In this longitudinal analysis and modelling study, we included two longitudinal cohorts of patients with first-
episode psychosis presenting to English early intervention services from defined catchments: NEDEN (recruiting 
1003 patients aged 14–35 years from 14 services between Aug 1, 2005, and April 1, 2009) and Outlook (recruiting 
399 patients aged 16–35 years from 11 services between April 1, 2006, and Feb 28, 2009). Patients were assessed at 
baseline, 6 months, and 12 months with the Positive and Negative Symptom Scale (PANSS), Calgary Depression 
Scale for Schizophrenia, Mania Rating Scale, Insight Scale, and Social and Occupational Functioning Assessment 
Scale. Regression was used to compare different models of the relationship between duration of untreated psychosis 
(DUP) and total symptoms at 6 months. Growth curve models of symptom subscales tested predictions arising from 
our hypotheses.
Findings We included 948 patients from the NEDEN study and 332 patients from the Outlook study who completed 
baseline assessments and were prescribed dopamine antagonist antipsychotics. For both cohorts, the best-fitting 
models were logarithmic, describing a curvilinear relationship of DUP to symptom severity: longer DUP predicted 
reduced treatment response, but response worsened more slowly as DUP lengthened. Increasing DUP by ten times 
predicted reduced improvement in total symptoms (ie, PANSS total) by 7·339 (95% CI 5·762 to 8·916; p<0·0001) in 
NEDEN data and 3·846 (1·689 to 6·003; p=0·0005) in Outlook data. This was true of treatment response for all 
symptom types. Nevertheless, longer DUP was not associated with worse presentation for any symptoms except 
depression in NEDEN (coefficients 0·099 [95% CI 0·033 to 0·164]; p=0·0028 in NEDEN and 0·007 [−0·081 to 0·095]; 
p=0·88 in Outlook).
Interpretation Long DUP was associated with reduced treatment response across subscales, consistent with a harmful 
process upstream of individual symptoms’ mechanisms; response appeared to worsen quickly at first, then more 
slowly. These associations underscore the importance of rapid access to a comprehensive range of treatments, 
especially in the first weeks after psychosis onset.
Funding UK Department of Health, National Institute of Health Research, and Medical Research Council.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4·0 license.
Introduction
Prolonged duration of untreated psychosis (DUP) predicts 
worse symptoms of all types and poorer social functioning 
and quality of life for 2 years1–3 after presentation or 
longer.4,5 Earlier detection improved outcomes in the quasi-
experimental TIPS study,6 as did introduction of specialist 
early intervention services,7–9 spurring intro duction of early 
treatment services worldwide. Yet the mechanism by 
which delayed treatment might cause harm remains 
unclear. Evidence of direct neurotoxicity is inconsistent.3,10,11
Symptoms could simply accumulate over time, 
worsening presentation. In the TIPS trial, for patients in 
the control areas that had longer DUP, psychosis and 
excitement were increased only at presentation, while 
depression and disorganisation were worse only at follow-
up, in proportion to their greater severity at presentation. 
Additionally, if exacerbation of one symptom worsens 
others, depending on which symptoms are primary, early 
monotherapy with antipsychotics, antidepressants, or 
lithium might mitigate a range of later problems.
DUP and outcome might be associated only via 
some unmeasured patient characteristic or residual 
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confounding. For example, people with illnesses that 
later become refractory might also tend to delay 
presentation, and observational studies might adjust 
incompletely for characteristics associated with both 
delay and poor out come (eg, insidious onset).12,13 Only 
randomised, blind-rated trials of interventions designed 
specifically to alter carefully measured DUP would 
eliminate that possibility.
Alternatively, during an initial critical period, continued 
psychosis could cause chronic, profound harm. Two studies 
have found that as DUP lengthened, total symptom 
response to treatment reduced quickly at first, then more 
slowly.13,14 Nonetheless, any delay might affect only specific 
systems or symptoms:10,11 Boonstra and colleagues’ meta-
analysis15 modelled this curvilinear relationship to negative 
symptoms specifically. It remains unclear how treatment 
delay affects other symptoms or whether this curve reflects 
gradual deceleration14,15 or a rapid, stepwise shift at some 
point.5,13
Since long DUP predicts a range of harms,1–6 we 
hypothesised that untreated psychosis causes generalised 
treatment resistance by exacerbating underlying illness 
processes, and that this damage progresses faster in 
the early stages of illness, decelerating over time as it 
approaches a natural limit, consistent with some previous 
evidence.13–15 We also hypothesised that socially dis ruptive 
symptoms before presentation might have a confounding 
effect—ie, severe excitement, hostility, and dysfunction 
could alarm people experiencing symptoms, and those 
around them, and lead to earlier presentation, in keeping 
with the little existing evidence available.12,14,16 These 
two hypotheses generate four testable conjectures: 
curvili nearity, generality, con founded presentation, and 
delay reversal.
The curvilinearity conjecture is that longer DUP will 
have a curvilinear relationship with symptoms, with the 
greatest increase in severity occurring early and a flattening 
of the curve as harm accumulates more slowly at longer 
DUP. The generality conjecture is that the profound effect 
of longer DUP on illness processes affects all symptom 
dimensions directly, rather than being mediated through 
specific ones. The confounded presentation conjecture 
stems from our prediction that longer DUP is likely to 
produce more severe, refractory illness, but once severe, 
disruptive symptoms develop, they speed up presentation 
for treatment.12,14,16 At this point, DUP’s association with 
worse symptoms is attenuated by severe symptoms’ 
tendency to shorten DUP. Nonetheless, adjusting for 
symptoms at presen tation, long DUP still predicts poor 
later response. Finally, the delay reversal conjecture is that 
the asso ciation of DUP with symptoms will differ 
according to the timing of initial assessments. Response to 
anti psychotics is largely complete within 6 weeks.17 Those 
first assessed soon after treatment starts will display the 
Research in context
Evidence before this study
We searched Embase, MEDLINE, and Ovid’s EBM databases in 
January, 2019, with no language restrictions using the terms 
(Schizophren* OR psychosis OR psychotic) AND (DUP OR 
“duration of untreated psychosis” OR “delayed treatment” OR 
“treatment delay” OR “treatment lag”) AND (2005–2019), 
yielding 855 titles: of these, 15 were relevant systematic reviews 
and 85 were articles describing first-episode cohort outcome 
studies after 2013 (the last meta-analysis being in 2014, and our 
last meta-analysis in 2005). Duration of untreated psychosis 
(DUP) correlated with worse symptoms and social functioning 
after presentation but not consistently with cognitive or cerebral 
volume change. Most studies assumed DUP and outcome to have 
a linear relationship: three suggested step-change or curvilinear 
relationships with overall or negative symptoms, none of which 
compared different models of the relationship with treatment 
delay or considered a range of outcomes. The quasi-experimental 
TIPS trial focused exclusively on reducing treatment delay in one 
catchment area, where symptoms were less severe at 
presentation than in two comparison areas, but thereafter only 
negative symptoms responded better to treatment.
Added value of this study
Models of the relationship of DUP with outcome were not 
consistent with linearity or mediation by specific symptoms. 
They were consistent with treatment delay worsening profound 
illness processes underlying all types of symptoms, with this 
deterioration being rapid at first but then slowing. 
The modelled effect of prolonging DUP by ten times was 
comparable to the difference between antipsychotics and 
placebo. Symptoms appeared to mediate the relationship with 
social functioning. The confounding effect of more severe 
symptoms accelerating initial presentation was considered for 
the first time, to our knowledge. Models were consistent with 
this affecting the relationship of DUP with presentation but not 
response. They also indicated a methodological artifact: reversal 
or attenuation of this pattern in those with first assessments 
delayed by more than 3 weeks after presentation.
Implications of all the available evidence
These findings explain previous meta-analytic findings and have 
implications for future first-episode cohort design and analysis. 
As our modelling is based on two observational studies, residual 
confounding or bias could account for our findings, but 
designing trials to test the specific effect of reducing delay 
presents particular methodological difficulties. For clinicians, 
service providers, and policymakers, this observational evidence 
implies that rapid, comprehensive intervention targeting all 
types of symptoms is most valuable if initiated within weeks of 
psychosis onset, when extra treatment delay is more harmful. 
Provided no immediate risks are identified, treating those 
presenting after years of untreated psychosis seems to be less 
urgent. For researchers, the timing of first assessments could be 
crucial to studies of (or merely adjusting for) the effect of DUP.
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patterns already conjectured (curvilinearity, generality, and 
confounded presentation), but when delays between 
treatment initiation and assessment approach 6 weeks or 
longer, symptoms at baseline assessment will reflect a 
combination of severity at initial presen tation and 
subsequent response to treatment. In this scenario, scores 
could now correlate with DUP because response influences 
baseline symptoms. As the bulk of response will have 
already occurred, any remaining symptom change will be 
dominated by random noise, so change will correlate little 
with DUP.
We tested these conjectures using data from two 
separate cohorts of patients with first-episode psychosis 
from the English National Health Service, where almost 
all incident psychosis cases are treated in National 
Institute for Health and Care Excellence-mandated early 
intervention services with defined catchment areas.18
Methods
Study design and participants
In this longitudinal analysis and modelling study, we used 
data from two longitudinal cohort studies. The National 
Evaluation of Development of Early intervention Network 
study (NEDEN) recruited patients aged 14–35 years and 
followed them up for 12 months after first episodes of 
functional psychosis. They were from defined areas served 
by 14 early intervention in psychosis services in England 
throughout Aug 1, 2005–April 1, 2009 (details published 
elsewhere).19 NEDEN participants met criteria for ICD-10 
mania or severe depression with psychotic symptoms, 
schizophrenia, schizoaffective disorder, delusional dis-
order, acute and transient psychotic disorders, drug-
induced psychoses, and psychosis not otherwise specified.
The Outlook study20 recruited from another 11 English 
early intervention in psychosis services with defined 
catchment areas, throughout April 1, 2006–Feb 28, 2009, 
with 12 months of follow-up. The inclusion criteria were 
age 16–35 years and diagnosis of ICD-10 mania or severe 
depression with psychotic symptoms, schizophrenia, 
schizoaffective disorder, delusional disorder, acute and 
transient psychotic disorders, drug-induced psychoses, 
and psychosis not otherwise specified; patients with 
organic brain disorders were excluded. Results from the 
Outlook data have not yet been published and will become 
available to other researchers, with the agreement of the 
investigators, 2 years after this publication, in line with 
MRC policy. Both studies had NHS Research Ethics 
Committee approval.
Procedures
Participants were recruited from consecutive first 
presentations as soon after first contact with the service 
as possible. Baseline assessment occurred as soon as a 
referral was received by a participating service, regardless 
of whether the potential participant was in hospital or the 
community. In practice, there was variation: in NEDEN, 
290 (32%) of 901 patients were assessed within 3 weeks 
of presentation and 611 (68%) after 3 weeks, whereas in 
Outlook, 69 (21%) of 332 patients were assessed within 
3 weeks and 263 (79%) later. 269 (28%) of the 948 patients 
in the NEDEN cohort started antipsychotics before entry 
into the early intervention service; this proportion is 
unknown for the Outlook cohort.
Outcomes
In both studies, graduate psychologists assessed 
participants at baseline and at 6-month and 12-month 
follow-up using the Positive and Negative Syndrome Scale 
(PANSS),21 Calgary Depression Scale for Schizophrenia,22 
Mania Rating Scale,23 Insight Scale24 (at baseline and 
12-month follow-up only), and the Social and Occupational 
Function Assessment Scale25 (SOFAS; at baseline and 
12-month follow-up only).
The two studies recorded sex, age, ethnic group, 
employment, education, and lifetime and current 
substance misuse, and NEDEN recorded living situation 
(eg, living alone, with a partner, or with parents or 
guardians). DUP was defined as the period from 
psychosis onset (requiring one PANSS positive item 
scoring ≥4, or two or more of delusions, disorganisation 
or hallucinations scoring >1 and totalling ≥7) to starting 
adequate antipsychotic treatment (defined as treatment 
that subsequently lasted 4 weeks, at a dose producing a 
response or meeting identified criteria; appendix p 2).19 
Prodrome was defined as the period from non-specific 
symptom onset to psychosis onset. Diagnosis was 
established at baseline in NEDEN and at 12 months in 
Outlook using the OPCRIT (Operationalised Criteria) 
computerised diagnostic system, a validated, reliable 
90-item checklist of symptoms rated from clinical 
notes.26
Statistical analysis
Selection bias for NEDEN is examined elsewhere19 (see 
also appendix p 5). Attrition bias was examined by logistic 
regression of all baseline demographic variables and 
scale scores against dropout at each stage in each cohort.
To test the curvilinearity conjecture within the NEDEN 
dataset, six a-priori regression models were compared for 
the relationship of DUP and PANSS after 6 months: 
stepped relationships contrasting DUP before and after 
either (1) 4 weeks or (2) 6 months; (3) a 4-week step 
followed by a linear relationship; (4) a classical linear 
relationship of DUP with PANSS; or a curvilinear 
relationship between DUP and PANSS modelled by a 
linear relationship with PANSS for (5) the square root of 
DUP or (6) log10DUP (appendix p 2). These models 
represent (1) a distinction between DUP matching criteria 
for affective psychosis and brief psychosis only, and DUP 
greater than 4 weeks consistent with schizophreniform, 
schizoaffective, and delusional disorders and schizo-
phrenia; (2) a distinction between DUP matching criteria 
for DSM-IV schizophrenia and all other disorders; 
(3) a model of minimal harm from brief psychoses and 
See Online for appendix
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steadily accumulating damage due to the others; 
(4) a model of linear increase in effect of delay—ie, the 
same harm from prolonging a DUP of 1 week by another 
week, as from prolonging a DUP of 208 weeks by another 
week; (5) a model of accumulating harm but decreasing 
extra damage as delay progresses, or staggered early and 
swift transitions in harm; and (6) a more radical model of 
deceleration. These models were compared using adjusted 
R², where a higher value indicates greater fraction of 
variance explained, and Akaike’s information criterion, a 
measure of fit and parsimony where lower AIC indicates a 
more successful model. These models were compared 
again in the subsample of NEDEN participants excluding 
primary ICD-10 bipolar and depressive disorders to 
examine the potential confounding effect of affective 
psychosis on DUP and outcome.
Principal axis factoring with promax rotation was used in 
the NEDEN dataset for items from PANSS, Mania Rating 
Scale, and Calgary Depression Scale for Schizophrenia and 
for the Insight Scale total at successive stages (appendix 
p 2). Six subscales were derived from equally weighted 
scores for all items loading consistently onto each factor 
(appendix pp 7–10) and labelled as negative, psychosis, 
depression, poor insight, excitement, and hostility.
Separate growth curve models (GCMs) were then 
formulated for PANSS total score and each subscale 
using generalised structural equation modelling (GSEM; 
appendix p 3). Each model included two latent variables: 
one modelling the intercept, reflecting baseline 
symptoms, and the other the slope of scores, reflecting 
change over follow-up. Since log10DUP had best predicted 
6-month outcome in the regression models and was 
consistent with the curvilinearity conjecture, it was 
included with potential demographic confounders as 
predictors of these latent intercepts and slopes to test the 
generality and confounded presentation conjectures.
Throughout the modelling process, to test the delay 
reversal conjecture, the sample was divided a priori into 
those first assessed within 3 weeks of presentation to 
services (the early group) and those first assessed later on, 
after the greatest reduction in symptoms with treatment 
had occurred (the late group). An interaction term 
(log10DUP × group) was used to test for and model 
differences between the early and late groups in the 
relationship of DUP to outcome. All analyses were 
repeated including length of prodrome as a potential 
confounder. Other sensitivity analyses are described in the 
appendix (p 3). To illustrate the impact of DUP on mean 
6-month PANSS change values, they were estimated 
using equations created from GSEM growth curve 
models, using the mean or most common value for the 
potential confounders in those models (ie, sex, age at 
onset, minority ethnicity, lifetime drug use, living alone, 
and education to A Level). To express the impact of DUP 
on PANSS change using a familiar metric, Hedge’s g was 
calculated by hand. The coefficient values from the GSEM 
models were used, with the values for n and PANSS SDs 
for the NEDEN early and late groups at baseline and first 
follow-up.
To test whether one symptom type mediated the effect 
of log10DUP on the other symptoms, disconfirming 
generality, we included different scales in three parallel 
growth process models, each essentially a combination 
of three GCMs fitted using classical structural equation 
modelling methods (rather than GSEM). Subscales were 
included that had relatively high partial correlations 
between them (appendix p 11).
To model social functioning, log10DUP, baseline sub-
scale scores, and demographic variables were regressed 
against baseline and final SOFAS, with backwards 
elimination. Pearson’s r was used to assess correlation 
(appendix p 4).
All GSEM and SOFAS models were then refitted in the 
Outlook dataset, using identical model specifications and 
freely varying coefficients. All analyses were done with 
Stata 14.1.
Role of the funding source
The NEDEN study was funded by the UK National 
Institute of Health Research and the Outlook study by 
the UK Medical Research Council. Neither funder had 
any role in data processing, the formulation of the 
hypotheses, analyses or interpretation of the findings, or 
writing of the paper. No authors were paid to write this 
Article by a pharmaceutical company or other agency. 
The corresponding author had full access to all the study 
data and final responsibility for the decision to submit 
for publication.
Results
In the NEDEN study, 1003 participants met recruitment 
criteria. 991 (99%) completed all baseline assessments (see 
appendix p 5 for characteristics) and 948 (95%) were 
prescribed dopamine antagonist antipsychotics. Of these 
948 patients, 751 (79%) were assessed at 6-month follow-up 
and 719 (76%) at 12-month follow-up. On logistic regression 
of all demographic variables, scale totals, and log10DUP 
against 6-month attrition, only lifetime drug use (odds 
NEDEN: all 
participants (n=734)
NEDEN: non-affective 
psychosis (n=616)
Outlook: all 
participants (n=194)
Adjusted R² AIC Adjusted R² AIC Adjusted R² AIC
Step change at 4 weeks 0·013 6049 0·004 5089 0·008 1966
Step change at 26 weeks 0·029 6056 0·021 5089 0·002 1966
4 week step + linear effect 0·021 6044 0·018 5085 0·009 1612
Linear effect of DUP 0·021 6057 0·018 5092 0·009 1611
Square root of DUP* 0·038 6044 0·033 5082 0·026 1608
Log10DUP* 0·043 6041 0·032 5083 0·040 1605
AIC=Akaike information criterion. DUP=duration of untreated psychosis. PANSS=Positive and Negative Syndrome 
Scale. *Curvilinear relationships of DUP and 6-month PANSS.
Table 1: Models of the association of DUP and 6-month PANSS score in the original (NEDEN) and 
replication (Outlook) datasets
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ratio [OR] 1·84, 95% CI 1·14–2·96; p=0·012) significantly 
predicted dropout. For 12-month attrition, no variables 
were significantly predictive.
In the Outlook study, 399 participants consented to 
assessment and met criteria. 332 (83%) completed all 
baseline assessments (see appendix p 6 for characteristics) 
and were prescribed dopamine antagonist antipsychotics. 
238 (72%) of these 332 participants were assessed at 
6-month follow-up and 220 (66%) at 12-month follow-up. 
Only poor baseline insight (OR 0·84, 95% CI 0·73–0·96; 
p=0·0088) significantly predicted 6-month dropout, 
whereas abstaining from drugs (0·49, 0·31–0·76; 
p=0·0025) and being single (0·60, 0·49–0·74; p<0·0001) 
predicted 12-month attrition.
To test the curvilinearity conjecture, the relationship 
of DUP to follow-up PANSS score was modelled. 
Comparing different models of DUP and 6-month 
symptom scores indicated that in both NEDEN and 
Outlook cohorts, the logarithmic model fitted best, 
representing a curvilinear relationship of DUP to 
outcome (table 1). Sensitivity analysis including only 
Neden participants with non-affective psychosis found 
that log10DUP fitted better than a linear relationship, 
although the fit of the square root of DUP (also 
indicating a curvilinear relationship) was slightly better. 
There was no significant difference between log10DUP 
regression coefficients (difference −0·15, 95% CI 
−2·46 to 2·16; p=0·90) in those with and those with-
out schizo phrenia spectrum diagnoses (β=0·09 and 
β=0·06, respectively).
When examining GCMs of PANSS total in NEDEN 
data, we found, in accordance with the confounded 
presentation conjecture, that log10DUP had no significant 
association with PANSS latent intercept in those assessed 
within 3 weeks of presentation (table 2; appendix p 11). 
Log10DUP was significantly related to PANSS latent slope 
in the early group, with longer DUP predicting a lesser 
decrease in symptoms during follow-up.
In accordance with the delay reversal conjecture, DUP 
was significantly associated with latent PANSS total 
intercept (representing baseline symptoms) in the late 
group (table 2). Long DUP predicted significantly worse 
baseline symptoms, with a significant difference from the 
coefficient in the early group, whereas the coefficient for 
log10DUP against the latent PANSS slope was not 
significant, representing another clear difference from the 
early group (table 2). Another expression of log10DUP’s 
effect on 6-month PANSS change was standardised effect 
size, using Hedges’ g. The decrease in symptom improve-
ment in the early group was 0·31 (95% CI 0·24 to 0·37) for 
every point increase in log10DUP, which can be interpreted 
as a ten-times increase in DUP—eg, from 1 day untreated 
to 10 days; from 10 days to 14 weeks, 2 days; or from 
14 weeks, 2 days to 2 years, 9 months. For the late group, 
the decrease in symptom improvement was not significant 
(g=0·02, 95% CI −0·05 to 0·09; figure 1).
Log10DUP’s relationship with subscales largely 
replicated the pattern for PANSS total, consistent with 
the generality conjecture (table 2). Within the early group, 
positive coefficients with latent slopes over follow-up 
Early group Late group Early vs late p value*
Log10DUP coefficient (95% CI) p value Log10DUP coefficient (95% CI) p value
Latent intercepts
PANSS total −2·909 (−5·860 to 0·041) 0·053 1·271 (0·564 to 1·978) 0·0004 0·018
Negative −0·029 (−0·102 to 0·044) 0·40 0·015 (−0·005 to 0·034) 0·14 0·30
Psychosis −0·017 (−0·055 to 0·022) 0·39 0·052 (0·010 to 0·093) 0·015 0·041
Poor insight −0·154 (−0·282 to −0·027) 0·018 −0·011 (−0·065 to 0·043) 0·69 0·0042
Depression 0·099 (0·033 to 0·164) 0·0028 0·008 (−0·010 to 0·026) 0·38 0·0024
Hostility −0·057 (−0·110 to −0·004) 0·034 0·009 (−0·024 to 0·042) 0·60 0·076
Excitement −0·215 (−0·276 to −0·154) <0·0001 −0·015 (−0·050 to 0·021) 0·42 <0·0001
Latent slopes
PANSS total 7·339 (5·762 to 8·916) <0·0001 0·347 (−0·766 to 1·460) 0·54 <0·0001
Negative 0·064 (0·017 to 0·110) 0·0066 0·007 (−0·021 to 0·035) 0·61 0·029
Psychosis 0·205 (0·139 to 0·270) <0·0001 0·031 (−0·010 to 0·072) 0·19 <0·0001
Poor insight 0·155 (0·054 to 0·256) 0·0026 0·028 (−0·001 to 0·056) 0·053 0·0054
Depression 0·056 (0·004 to 0·108) 0·034 0·034 (0·008 to 0·061) 0·011 0·42
Hostility 0·128 (0·051 to 0·206) 0·0065 −0·008 (−0·039 to 0·023) 0·62 0·0046
Excitement 0·224 (0·159 to 0·289) <0·0001 −0·001 (−0·037 to 0·036) 0·96 <0·0001
All models are GCMs of the natural logarithm of the variable at each stage, clustered by centre, apart from PANSS total, which is a GCM of PANSS total without the natural 
logarithm. Models are adjusted for centre, sex, age, ethnic minority status, education, drug use, and living alone. Latent intercepts represent baseline symptom scores, with 
more positive coefficients indicating higher scores; latent slopes represent symptom change over follow-up, with more positive coefficients indicating reduced improvement 
(less negative symptom change). PANSS=Positive and Negative Syndrome Scale. GCM=growth curve model. DUP=duration of untreated psychosis.*Significance of test 
contrasting early and late group coefficients for log10DUP regressed against latent variable, indicative of delay reversal.
Table 2: Models of symptom intercepts and change in the NEDEN dataset for groups first assessed early or late
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indicated that longer log10DUP was associated with 
significantly less improvement (figure 2). Meanwhile, 
latent intercepts had negative coefficients, indicating that 
shorter log10DUP was, if anything, associated with worse 
baseline symptoms when measured soon after presen-
tation, consistent with the confounded presentation 
conjecture (table 2). The exception was depression: longer 
log10DUP was associated with both higher latent intercept 
and less latent reduction over follow-up (table 2).
Comparing late and early groups, the delay reversal 
conjecture implied that coefficients for intercepts would 
be higher in the late group (because long DUP leads to 
higher symptom scores after treatment, and for patients 
with late baseline assessments, treatment effects have 
begun to influence scores) but coefficients for latent 
slope should be reduced (because late baseline assess-
ments miss early improvement, reducing long DUP’s 
effect on change scores). This was so for all subscales, 
with almost all differences between late and early groups 
being significant (table 2).
Prodrome duration was not recorded in 32 patients with 
otherwise complete data; it was included in NEDEN 
GCMs of the total PANSS and all subscales to test 
sensitivity to insidious onset. It made little difference to 
any of the coefficients obtained for log10DUP and was 
significantly related to only psychosis, hostility, and 
depression latent intercepts, and no latent slopes (analyses 
available on request). Alternative specifications of GCMs 
all fitted more poorly (appendix p 3). Models combining 
clustering within centres and main effects of centre fitted 
better than simpler multilevel versions, making little 
difference to coefficients for DUP with symptoms.
To test the generality conjecture in NEDEN, we 
examined log10DUP’s relationship to subscales using 
parallel growth process models. For the first model, 
psychosis, depression, and poor insight were modelled 
simultaneously, with latent intercepts and latent slopes 
covarying within each subscale (appendix p 4). This 
process was repeated for models of psychosis, depression, 
and negative symptoms and of psychosis, hostility, and 
excitement (appendix p 12). In these three models, 
log10DUP’s independent association in the early group 
was again significantly positive with every latent slope 
and significantly negative with the poor insight, hostility, 
and excitement latent intercepts; the only positive latent 
intercept in the early group was for depression, although 
the association was not significant (appendix p 12). Again, 
few associations with the late group latent variables were 
significant, all of which were positive (appendix p 12).
When these models were fitted to Outlook data, the 
pattern of coefficients was very similar to that in NEDEN, 
although in this smaller cohort, 95% CIs were wider 
(table 3). In the early group, the PANSS total latent 
intercept was non-significantly negatively correlated with 
log10DUP, whereas the latent slope was significantly 
positively associated (ie, longer DUP predicted reduced 
improvement in scores). Meanwhile, in the late group, 
longer log10DUP was significantly associated with higher 
latent PANSS intercept but not slope (ie, long DUP 
predicted worse symptoms at late baseline assessments 
but not change).
Symptoms appeared to mediate treatment delay’s 
effect on social function. We found that greater log10DUP 
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Figure 1: Latent change in PANSS total score against DUP over 6 months in NEDEN participants first assessed 
early and late
The blue diamonds indicate participants assessed within 3 weeks of presentation (early assessment) and the red 
circles indicate those assessed more than 3 weeks after presentation (late assessment). Shaded areas represent 
95% CIs. Only the first 3 years of DUP are shown. PANSS total score ranges from 30 to 210, where an increase in 
score indicates more severe symptoms. Predictions are calculated at mean values for potential confounders. 
DUP=duration of untreated psychosis. PANSS=Positive and Negative Syndrome Scale.
Figure 2: Predicted change in untransformed symptom scale scores over 6 months as a proportion of 
baseline, against DUP
Symptom change was calculated from natural log-transformed scores adjusted for centre, drug use, 
and demographics. Only the first 3 years of DUP are shown. DUP=duration of untreated psychosis.
Articles
608 www.thelancet.com/psychiatry   Vol 7   July 2020
correlated significantly with poorer baseline SOFAS in 
the NEDEN late group (r = −0·08; p=0·047) but not in the 
early group, and correlated significantly with poorer final 
SOFAS in both groups (early group r = −0·21; p=0·0010; 
late group r = −0·11; p=0·019). In multiple regressions 
against baseline and final SOFAS, symptoms but not 
log10DUP had independent relationships with SOFAS in 
each NEDEN group, as in Outlook (appendix p 13).
Discussion
These findings from our longitudinal analysis and 
modelling study support the hypothesis that harm 
incurred by treatment delay is greatest in the early weeks 
of psychosis, levelling off towards a maximum as DUP 
increases, given the improved fit of the model representing 
curvilinear relationship of DUP with PANSS (ie, cur-
vilinearity conjecture). The effect size for a ten-times 
increase in DUP on the early group’s latent change 
(g=0·31) appeared comparable to that for placebo versus 
lurasidone (for which g=0·33),27 implying that this increase 
in the delay before receiving treatment predicts a difference 
in symptoms comparable to placebo versus antipsychotics.28 
DUP’s direct, curvilinear association with response fitted 
all symptom types (ie, generality conjecture). Parallel 
growth process analyses were consistent with GCMs, 
confirming that DUP had an independent association with 
change in each symptom dimension even after adjusting 
for inter-correlations between symptoms.
Consistent with our confounded presentation con-
jecture, in those first assessed soon after presentation, 
long DUP predicted poor recovery but not worse baseline 
scores. In this group, in the NEDEN cohort but not the 
Outlook cohort, worse baseline hostility, excitement, and 
insight were significantly associated with shorter DUP, 
suggesting that they accelerated presentation, consistent 
with some previous findings.14,16 DUP was, however, 
associated with both worse presentation and poorer 
recovery of depres sion. Consistent with the delay reversal 
conjecture, in the late group, DUP was associated with 
higher baseline scores (intercept coefficients) and lower 
change scores (slope coefficients) for almost all variables. 
There were two exceptions (intercept for depression in 
NEDEN, intercept for poor insight in Outlook) and many 
of the early versus late contrasts in the smaller Outlook 
dataset were not significant.
Our results provide no insights into those with at-risk 
mental states who might develop psychosis but argue 
that indicated prevention in those who have psychotic 
symptoms is important to prevent treatment delays 
from limiting recovery across whole populations. As 
the effect of treatment delay generalised across 
symptoms, its effect appeared to be upstream of the 
specific mechanisms underlying each symptom 
dimension. That untreated psychosis displayed a 
delayed association with refractory illness, rather than 
its effect being mediated by severity at presentation, 
was also consistent with delay causing a profound 
worsening of underlying illness processes instead of its 
effect being mediated by accumulation of symptoms 
until presentation.
Early group Late group Early vs late p value*
Log10DUP coefficient (95% CI) p value Log10DUP coefficient (95% CI) p value
Latent intercepts
PANSS total −0·327 (−1·806 to 1·151) 0·66 1·665 (0·395 to 2·935) 0·010 0·0053
Negative −0·008 (−0·041 to 0·024) 0·61 0·009 (−0·009 to 0·026) 0·35 0·45
Psychosis −0·003 (−0·068 to 0·063) 0·93 0·052 (0·010 to 0·093) 0·014 0·23
Poor insight 0·007 (−0·090 to 0·104) 0·89 −0·020 (−0·056 to 0·015) 0·25 0·55
Depression 0·007 (−0·081 to 0·095) 0·88 0·013 (−0·012 to 0·038) 0·30 0·89
Hostility −0·022 (−0·054 to 0·010) 0·18 0·047 (0·026 to 0·068) <0·0001 0·0022
Excitement −0·071 (−0·142 to 0·001) 0·052 0·005 (−0·019 to 0·030) 0·66 0·048
Latent slopes
PANSS total 3·846 (1·689 to 6·003) 0·0005 0·876 (−0·083 to 1·835) 0·073 0·026
Negative 0·044 (0·008 to 0·080) 0·018 0·009 (−0·016 to 0·034) 0·50 0·17
Psychosis 0·097 (0·009 to 0·185) 0·032 0·024 (−0·005 to 0·052) 0·099 0·19
Poor insight 0·071 (0·042 to 0·100) <0·0001 0·027 (−0·016 to 0·069) 0·22 0·039
Depression 0·059 (−0·010 to 0·128) 0·094 0·045 (0·006 to 0·084) 0·023 0·79
Hostility 0·050 (0·010 to 0·091) 0·015 −0·012 (−0·036 to 0·011) 0·31 0·036
Excitement 0·058 (−0·006 to 0·121) 0·076 1·665 (0·395 to 2·935) 0·010 0·26
All models are GCMs of the natural logarithm of the variable at each stage, clustered by centre, apart from PANSS total, which is a GCM of PANSS total without the natural 
logarithm. Models are adjusted for centre, sex, age, ethnic group, education, drug use and living alone. Latent intercepts represent baseline symptom scores, with more 
positive coefficients indicating higher scores; latent slopes represent symptom change over follow-up, with more positive coefficients indicating reduced improvement (less 
negative symptom change). PANSS=Positive and Negative Syndrome Scale. GCM=growth curve model. DUP=duration of untreated psychosis.*Significance of test 
contrasting early and late group coefficients for log10DUP regressed against latent variable, indicative of delay reversal.
Table 3: Models of symptom intercepts and change in the Outlook dataset for groups assessed early or late
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Although this study cannot investigate what the toxic 
processes might be, the conflicting literature detailing 
specific brain changes associated with delay or transition 
to psychosis provides potential indications.10,11 No well 
evidenced treatments target such profound processes, so 
comprehensive early treatment for all symptoms 
exacerbated by treatment delay is indicated: no single 
therapy will improve them all. This is consistent with 
Golay and colleagues’ finding28 that insofar as initiating 
antipsychotics and initiating specialist care were separate 
events, delay in achieving specialist care combined with 
antipsychotics was the best predictor of response.
That DUP only indirectly affected social functioning 
contradicted previous findings of DUP’s directly affecting 
social functioning after adjustment for symptoms in 
schizophrenia.29 Our study had more comprehensive 
measures of symptoms and larger numbers but an 
inferior measure of social function and included all 
psychoses, so reasons for the difference are unclear. Our 
finding was inconsistent with neurocognitive deficits (or 
other confounders) progressing during treatment delay 
and affecting social function, but consistent with other 
findings that DUP is unrelated to overall neurocognition.10
Modelling of data from such observational studies 
cannot ascertain whether the symptom–DUP curve at 
group level reflects harm accumulating at a gradually 
diminishing rate in each individual. For instance, abrupt 
step changes in the rate of harm for individuals could 
produce a gradual curve at group level if steps are 
staggered across the population, with most occurring 
early and then with decreasing frequency.
There are other limitations. The associations found 
could be artifacts of confounding or bias. There was no 
evidence that our results were due to diagnostic 
differences (eg, affective disorder or brief psychoses 
having shorter DUP and better outcomes): DUP’s 
curvilinear relationship was similar between schizo-
phrenia spectrum and other diagnoses. We attempted to 
adjust for the effects of centre, demographics, and drug 
use. There was little evidence that adjusting for prodrome 
duration (ie, insidious onset) altered our findings. 
Although GCMs depended on a range of assumptions 
(appendix p 3), other models with different assumptions 
fitted less well and core findings were insensitive to the 
differences between GSEM and SEM—ie, the growth 
curve and parallel process models yielded similar results 
(table 2; appendix p 11). There were also potential 
selection biases introduced by individuals not presenting 
to services, declining to enter the cohorts, or dropping 
out. There was little evidence of differences between 
those who were recruited and those who declined in 
NEDEN (no such data were available for Outlook).19 
There was also little evidence of bias in comparisons 
across different stages of assessment and the analysis 
chosen is robust in the face of data apparently missing at 
random. Finally, rare but important outcomes including 
suicide and homicide were not included.
The distinction in findings between those assessed 
early and late meant that some conclusions were based 
on the subsample assessed before the bulk of treatment 
effects had occurred. Of relevance to future studies, this 
distinction between findings depending on timing of first 
assessment implies that timing of first assessment might 
contribute to differences in findings across the field.2,3,10
A recent meta-analysis of trials of varied interventions to 
reduce DUP found only two randomised controlled trials 
among several studies comparing interventions to existing 
early intervention services, and no significant overall 
effect.30 The area is beset with methodological problems, 
such as successful interventions seemingly specific to 
particular service contexts, and community campaigns to 
encourage early attendance attracting outliers with long 
DUP unknown to control services. Our findings underline 
the importance of using a suitable transformation of DUP 
as outcome (eg, ln(DUP)), both to reduce the influence of 
such outliers on effect sizes and to reflect the lesser 
treatment benefit of reducing long DUP.
In conclusion, treatment delay was associated with 
impaired recovery in every symptom dimension, with 
latent harm appearing to develop rapidly during a relatively 
critical period soon after transition to psychosis, then more 
slowly as psychosis continued. The key public health 
implication of our hypotheses is that services might 
consider a focus on the early detection and treatment of 
those whose DUP is already short, even though there is no 
evidence of the effect of enacting this policy or about rare, 
serious outcomes such as suicide. This longitudinal 
analysis and modelling study does no more than identify a 
series of associations consistent with its hypotheses. What 
adds to its significance is the face validity of shortening 
treatment delay and the difficulty of implementing more 
rigorous investigations—eg, randomised, blind-rated trials 
of interventions that shorten only already short treatment 
delays. As DUP was associated directly with all symptoms, 
rapid access to comprehensive treatment might be 
preferable to early delivery of particular treatments with 
particular effects (eg, dopamine antagonists). Finally, we 
might expect mechanistic hypotheses for DUP’s toxicity to 
predict this curvilinear effect on response across 
symptoms.
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